AAAAAA
Results:
1-18
|
Results: 18
Authors:
Twelves, C
Boyer, M
Findlay, M
Cassidy, J
Weitzel, C
Baker, C
Osterwalder, B
Jamieson, C
Hieke, K
Citation: C. Twelves et al., Capecitabine (Xeloda (TM)) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients withadvanced colorectal carcinoma, EUR J CANC, 37(5), 2001, pp. 597-604
Authors:
Propper, DJ
McDonald, AC
Man, A
Thavasu, P
Balkwill, F
Braybrooke, JP
Caponigro, F
Graf, P
Dutreix, C
Blackie, R
Kaye, SB
Ganesan, TS
Talbot, DC
Harris, AL
Twelves, C
Citation: Dj. Propper et al., Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C, J CL ONCOL, 19(5), 2001, pp. 1485-1492
Authors:
Van Cutsem, E
Twelves, C
Cassidy, J
Allman, D
Bajetta, E
Boyer, M
Bugat, R
Findlay, M
Frings, S
Jahn, M
McKendrick, J
Osterwalder, B
Perez-Manga, G
Rosso, R
Rougier, P
Schmiegel, WH
Seitz, JF
Thompson, P
Vieitez, JM
Weitzel, C
Harper, P
Citation: E. Van Cutsem et al., Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study, J CL ONCOL, 19(21), 2001, pp. 4097-4106
Authors:
Macleod, UM
Ross, S
Watt, GCM
Twelves, C
George, WD
Gillis, C
Citation: Um. Macleod et al., Management of women with early breast cancer - Authors' reply, BR MED J, 321(7273), 2000, pp. 1409-1409
Authors:
Macleod, U
Ross, S
Twelves, C
George, WD
Gillis, C
Watt, GCM
Citation: U. Macleod et al., Primary and secondary care management of women with early breast cancer from affluent and deprived areas: retrospective review of hospital and general practice records, BR MED J, 320(7247), 2000, pp. 1442-1445
Authors:
Macleod, U
Ross, S
Gillis, C
McConnachie, A
Twelves, C
Watt, GCM
Citation: U. Macleod et al., Socio-economic deprivation and stage of disease at presentation in women with breast cancer, ANN ONCOL, 11(1), 2000, pp. 105-107
Authors:
Van Cutsem, E
Findlay, M
Osterwalder, B
Kocha, W
Dalley, D
Pazdur, R
Cassidy, J
Dirix, L
Twelves, C
Allman, D
Seitz, JF
Scholmerich, J
Burger, HU
Verweij, J
Citation: E. Van Cutsem et al., Capecitabine, an oral fluoropyrimidine carbamate with substantial activityin advanced colorectal cancer: Results of a randomized phase II study, J CL ONCOL, 18(6), 2000, pp. 1337-1345
Authors:
Twelves, C
Anthoney, A
Citation: C. Twelves et A. Anthoney, Rational development of capecitabine, SEMIN ONCOL, 27(5), 2000, pp. 144-148
Authors:
Pronk, LC
Vasey, P
Sparreboom, A
Reigner, B
Planting, AST
Gordon, RJ
Osterwalder, B
Verweij, J
Twelves, C
Citation: Lc. Pronk et al., A phase I and pharmacokinetic study of the combination of capecitabine anddocetaxel in patients with advanced solid tumours, BR J CANC, 83(1), 2000, pp. 22-29
Authors:
Twelves, C
Glynne-Jones, R
Cassidy, J
Schuller, J
Goggin, T
Roos, B
Banken, L
Utoh, M
Weidekamm, E
Reigner, B
Citation: C. Twelves et al., Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites, CLIN CANC R, 5(7), 1999, pp. 1696-1702
Authors:
Vasey, PA
Kaye, SB
Morrison, R
Twelves, C
Wilson, P
Duncan, R
Thomson, AH
Murray, LS
Hilditch, TE
Murray, T
Burtles, S
Fraier, D
Frigerio, E
Cassidy, J
Citation: Pa. Vasey et al., Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents - Drug-polymer conjugates, CLIN CANC R, 5(1), 1999, pp. 83-94
Authors:
Mackay, HJ
Bissett, D
Twelves, C
Vasey, PA
Citation: Hj. Mackay et al., A pilot study of continuous infusional 5-fluorouracil, doxorubicin and cyclophosphamide in breast cancer, CL ONCOL-UK, 11(3), 1999, pp. 174-178
Authors:
Stevenson, JP
DeMaria, D
Sludden, J
Kaye, SB
Paz-Ares, L
Grochow, LB
McDonald, A
Selinger, K
Wissel, P
O'Dwyer, PJ
Twelves, C
Citation: Jp. Stevenson et al., Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion, ANN ONCOL, 10(3), 1999, pp. 339-344
Authors:
Twelves, C
Citation: C. Twelves, UFT plus calcium folinate/irinotecan in colorectal cancer, ONCOLOGY-NY, 13(7), 1999, pp. 51-54
Authors:
Cassidy, J
Twelves, C
Cameron, D
Steward, W
O'Byrne, K
Jodrell, D
Banken, L
Goggin, T
Jones, D
Roos, B
Bush, E
Weidekamm, E
Reigner, B
Citation: J. Cassidy et al., Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients, CANC CHEMOT, 44(6), 1999, pp. 453-460
Authors:
Eatock, M
Church, N
Harris, R
Angerson, W
McArdle, C
French, R
Twelves, C
Citation: M. Eatock et al., Activity of doxorubicin covalently bound to a novel human serum albumin microcapsule, INV NEW DR, 17(2), 1999, pp. 111-120
Authors:
Thavasu, P
Propper, D
McDonald, A
Dobbs, N
Ganesan, T
Talbot, D
Braybrook, J
Caponigro, F
Hutchison, C
Twelves, C
Man, A
Fabbro, D
Harris, A
Balkwill, F
Citation: P. Thavasu et al., The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients, CANCER RES, 59(16), 1999, pp. 3980-3984
Authors:
Thomson, AH
Vasey, PA
Murray, LS
Cassidy, J
Fraier, D
Frigerio, E
Twelves, C
Citation: Ah. Thomson et al., Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours, BR J CANC, 81(1), 1999, pp. 99-107
Risultati:
1-18
|